Category Archives: Schizophrenia

Schizophrenic man jailed for double murder

September 26, 2012     No comments

Schizophrenic man jailed for double murder
He began hearing voices talking to him on the radio and saw images of his wife's dead body on television before being diagnosed with paranoid schizophrenia and treated with anti-psychotic medication. But following a relapse in 2006 during which he was …
Read more on Ninemsn

Local NAMI branch marks 30th year of demystifying mental illness
Gary Harrelson, who has schizophrenia, likes to compare the voices he often hears to having an ex-wife in his head. The voices constantly point out his faults and the faults of others around him. Harrelson, 50, of Springfield, frequently visits NAMI of …
Read more on Springfield News-Leader

WYANDOTTE: Schizophrenic man missing from group home found(UPDATED)
WYANDOTTE — A 53-year-old group home resident that suffers from schizophrenia has been missing since Saturday. Jeffrey Harbin lives at Hill's Support Services, 600 Oak Street. The home houses many people suffering from mental disabilities. Harbin …
Read more on Southgate News Herald

Read More

Michael Brownstein to speak on "Schizophrenia: the Soul Thief"

September 25, 2012     No comments

Michael Brownstein to speak on "Schizophrenia: the Soul Thief"
Brownstein, whose family foundation has contributed startup funds to the Block Island Mental Health Task Force telemedicine program, is scheduled to speak on schizophrenia on September 18. He notes his parents first started coming to the island when he …
Read more on Block Island Times

'Schizophrenic' France faces wrath of Syria
AP. FSA soldiers help a severely wounded colleague after being shot by a Syrian Army sniper in Izaa district in Aleppo, Syria, Saturday, Sept 8, 2012. On Friday, U.S. Senators John McCain, Joe Lieberman and Lindsay Graham, who have toured the volatile …
Read more on Himalayan Times

Read More

Feinstein Investigators Receive Federal GO Grant to Study the Genetics of Schizophrenia

August 11, 2012     No comments


Manhasset, NY (Vocus) October 10, 2009

The National Institutes of Health (NIH) has awarded a ?Grand Opportunity? (GO) grant to a team of researchers ? led by Todd Lencz, PhD, at The Feinstein Institute for Medical Research and Ariel Darvasi, PhD, of Hebrew University ? to use cutting-edge technologies to help unravel the genetic basis of schizophrenia. More than two million dollars was awarded to the team, which also includes Anil Malhotra, MD, and Peter Gregersen, MD, of the Feinstein Institute and David Goldman, MD, of the National Institute of Alcohol Abuse and Alcoholism, to conduct this research.

As described by the NIH, the GO grant program was designed to support ?high impact ideas? that can ?accelerate critical breakthroughs? in our understanding of human disease. The program was made possible by an infusion of money to the NIH under the American Recovery and Reinvestment Act (also known as the ?economic stimulus package?), representing ?the single largest boost to biomedical research in history,? according to President Barack Obama. In announcing the awards, President Obama singled out genetic research as ?one of the most exciting areas of research to move forward as a result of this investment.? Eventually, it is hoped that this research may be used to more accurately predict, treat, and prevent serious mental illnesses such as schizophrenia.

It has long been known that schizophrenia ? a complex brain disease marked by hallucinations and delusions ? tends to run in families and therefore has a genetic component to its cause. However, scientists have struggled to conclusively identify the genes that contribute to risk for this disease. ?Current evidence suggests that many genes are likely to be involved in schizophrenia, which theoretically should provide a large target for scientists,? Dr. Lencz said. ?Unfortunately, these genes are individually either very rare or very weak in effect, making them very elusive to traditional forms of genetic analysis.?

The newly funded GO grant builds on prior gene-hunting efforts with several distinctive features. Most notably, the sample consists entirely of individuals (patients and controls) of Ashkenazi Jewish descent, recruited in Israel by Dr. Darvasi, who explains ?The unique demographic history of the Jewish Ashkenazi population results in a more homogeneous genetic background compared to the general population. This should allow disease-related genetic signals to stand out more clearly in our analyses.? Additionally, this study will utilize the most advanced genetic technologies, which will permit examination of many more pieces of the genetic code than prior generations of research.

###





Related Schizophrenia Press Releases

Read More

Erica Karas Writes Book, The Holy One of Israel

August 11, 2012     No comments

Halethorpe, Md. (PRWEB) October 21, 2009

Holy Fire Publishing (http://www.christianpublish.com ) releases The Holy One of Israel (Casebound, US$ 24.00, ISBN#978-1-60383-184-0). Erica Karas writes of salvation’s impact on spiritual and mental health.

The Holy One of Israel depicts Erica Karas’ spiritual journey, focusing on the impact of Jesus’ earthly life, God’s nature and the Holy Spirit on the Christian’s spiritual and mental health. One day the Holy Spirit told Karas, at least she thought, “Kneel at the altar”. She obeyed and prayed at her churches’ altar for seven days. Finally, the Holy Spirit interpreted this foreign tongue, “Come to the Water.” Karas, immediately, understood that the “Water” was the Word of God. This is when Karas’ spiritual journey with our Lord intensified. Since then, He has miraculously led her to Scriptures for guidance, wisdom and healing. In The Holy One of Israel, Karas recounts her relationship with God and shares the wisdom and knowledge gained from this relationship in order to increase the believing reader’s faith and draw nonbelievers to Christ.

“Countless children are damaged from trauma, fear, rejection, lack of affirmation, incest, hatred, envy, jealousy, abandonment, poverty; the list is extensive. Jesus came to restore us. He wants to remove all the stains life has left on each of us. He wants to deliver us from bondage: it can be resentment, unforgiveness, or lying; it doesn’t matter. He did not come to condemn but to free and forgive us. We can stay bound to our past and let it destroy us, or we can use it with His power to release others. Our testimony always comes out of our test in life. It can take years for this scripture, “all things are become new” (2 Cor. 5:17), to be fulfilled in our lives. All things did not become new for me instantly, but as I continue my walk with my Lord, all things are becoming new in my soul and life ? [we may] have issues after salvation and need God’s delivering power to set us free. It is in the spirit where “all things become new,” but between man’s spirit and his mind are all the things that ? have to go so we can be totally free. This is what I have found to be true in my life journey with the Lord: He desires for each of us to know and walk with the Comforter; and to open our hearts and minds to Him, and to let the Holy Spirit guide us through our journey. God wants us to know his plan for our lives, intimately, through the third person of the Trinity.”– Erica Karas

The Holy One of Israel includes Karas’ experiences from a recent trip to the Holy Land. She shares pictures of the Apostle Peter’s home; the Sea of Galilee; the Ziziphus spina-christi tree, whose branches formed the crown of thorns; Golgotha, “the place of the skull”; and Jesus’ open tomb.

Dr. Erica Karas, a certified psychiatric pharmacist specialist, chose her profession out of tribute to her father who battled with schizophrenia. An ordained evangelist, Dr. Karas serves the Lord through writing and teaching. She and her husband, David, an accountant, and their cat Angel live in Halethorpe, Maryland. Currently, they attend St. Mark’s Catholic Church in Baltimore. Dr. Karas is active in the women’s ministry at New Beginnings Community Outreach in Baltimore. Visit her website at http://www.holyoneofisrael.net

Holy Fire Publishing (http://www.christianpublish.com), publisher of hundreds of Christian books, helps Christian authors reach the world through the printed word.

###







Related Schizophrenia Press Releases

Read More

Title Offers Revolutionary Leap in Understanding of Mental Illness

August 10, 2012     No comments

Longwood, FL (PRWEB) October 24, 2009

For years, the cause of mental illness and its remedy have remained shrouded in mystery–until now. Xulon Press author Joan Richardson’s A Thorn in My Flesh ($ 16.99, paperback, 978-1-61579-267-2) smiths a new key that unlocks the mystery of schizophrenia, offering hope, faith, and understanding to Christian families that struggle beneath the burden of mental illness. This autobiography chronicles the author’s 40-year journey through the wilderness of schizophrenia, detailing how she has met her struggles with persevering faith. Her progressive victories over the devastation of mental illness are inspirational.

“Readers will gain insight about the Christian life,” the evangelist explains. “Seekers will find answers and believers will discover empowerment, renewal, and victory. The hopeless will find hope; the addict, freedom. Those determined in their Christian faith will find release from mental illness.”

A radio station owner, artist, and motorcyclist–as well as the former co-host of the contemporary Christian radio show “Man Alive!”–Richardson and her new book represent a stunning, revolutionary leap in understanding mental health and wholeness. “This autobiography springs from a life that could have ended in despair, but instead emerges with joy,” she explains, promising that the God who watches over her will watch over all who believe.

Joan Richardson currently resides in Delaware with her husband Bob.

Xulon Press, a division of Salem Communications, is the world’s largest Christian publisher, with more than 7,000 titles published to date. Retailers may order A Thorn in My Flesh through Ingram Book Company and/or Spring Arbor Book Distributors. A Thorn in My Flesh is available online through xulonpress.com/bookstore, amazon.com, and barnesandnoble.com.

# # #



More Schizophrenia Press Releases

Read More

Antipsychotic Medications Cause Substantial Weight Gain in Children and Adolescents, According to Scientists at the Feinstein Institute for Medical Research and Zucker Hillside Hospital

August 10, 2012     No comments


Manhasset , NY (Vocus) October 28, 2009

It has been known for several years that antipsychotic medications can cause weight gain in adults and increase the risk for serious metabolic disorders. Scientists at The Zucker Hillside Hospital and The Feinstein Institute for Medical Research embarked on a large study following children and adolescents who have been prescribed antipsychotic medicines for the first time and examining the impact they had on weight gain and metabolic changes. Indeed, researchers identified a worrisome degree of weight gain and caution their colleagues to take these changes seriously. Weight gain and changes in blood glucose and lipid metabolism can be precursors of diabetes, hypertension, metabolic syndrome, stroke and heart attack. The children tested were between 4-19 years old.

“The data sheds further light on the frequency and severity of weight gain associated with these newer antipsychotics,” said Christoph U. Correll, MD, medical director of the Recognition and Prevention (RAP) program at the Zucker Hillside Hospital and a scientist in the Feinstein Institute’s Center for Psychiatric Neuroscience. “Our findings suggest increased caution in prescribing them to pediatric patients.”

The scientists studied 272 young people who had been prescribed antipsychotic medicines for a range of serious behavioral, mood and psychosis-related problems. The patients were prescribed one of a number of second-generation antipsychotics and followed over the first 12 weeks to assess changes in weight, blood glucose and lipids. At around 11 weeks, the young patients had gained an average of 19 pounds on the antipsychotic, olanzapine; 13.5 pounds on quetiapine; 11.9 pounds on risperidone; and 9.9 pounds on aripiprazole. By comparison, 15 patients who refused participation in the study or were not compliant with taking the antipsychotics were used as a control group and their weight gain during the same study period was less than a half-pound.

The findings were published this week in the Journal of the American Medical Association (JAMA).

The scientists also identified substantial changes in triglycerides and cholesterol, and found that the weight gain alone did not seem to explain entirely the adverse metabolic effects that varied significantly across the individual medications. All of the findings, Dr. Correll said, “should be considered when choosing antipsychotics.” SATIETY (Second-Generation Antipsychotic Treatment Indications, Effectiveness and Tolerability in Youth) is the largest cohort study of atypical antipsychotic treatment in children and adolescents treated with antipsychotics. It is also the largest study of its kind in children or adults who received antipsychotic treatment for the first time in their life. This is a key study feature because prior treatment can obscure the true cardiometabolic effects of medications. In the SATIETY study, the antipsychotic-na?ve youths suffered from a range of problems, including psychosis (30.1 percent,) mood disorders (47.8 percent) and aggressive behavior (22.1 percent). Researchers followed these patients to understand if weight and metabolic changes are due to the new onset of a psychiatric illness or related hospital admission, or whether the observed changes are effects of the antipsychotic treatment.

The scientists found that the worsening of metabolic parameters differed between the antipsychotic medications groups, despite the shared, large and significant changes in body weight parameters, including waist circumference. Olanzapine, which was also associated with the largest effects on body weight, was associated with the greatest and most widespread worsening of lipid as well as glucose parameters. Quetiapine and risperidone were associated with varying degrees of lipid abnormalities only, which were more pronounced with quetiapine. By contrast, aripiprazole was not associated with any significant worsening in glucose or lipid parameters, which was also the case in the comparison subjects. “These findings provide further evidence for an additional, weight independent mechanism for glucose and lipid abnormalities with olanzapine that does not seem to be shared by the other antipsychotics that were studied,” said Dr. Correll.

Antipsychotic medication use in young people has grown substantially in recent years and this study calls into question the effects of this upward trend. “Abnormal childhood weight and metabolic status adversely affect adult cardiovascular outcomes via continuation of these risk factors or independent or accelerated mechanisms,” the scientists wrote. “Our results, together with data from first-episode studies, suggest that guidelines for antipsychotic medication exposure for vulnerable pediatric and adolescent patients naive to antipsychotic medication should consider more frequent (e.g., biannual) cardiometabolic monitoring after the first three months of treatment. Finally, in view of poor physical health outcomes and suboptimal metabolic monitoring in the severely mentally ill, the benefits of second-generation antipsychotic medications must be balanced against their cardiometabolic risks through a careful assessment of the indications for their use, consideration of lower-risk alternatives, and proactive adverse effect monitoring and management.”

In an accompanying editorial, Christopher K. Varley, M.D., and Jon McClellan, M.D., of Seattle Children’s Hospital, said that while “these medications can be lifesaving for youth with serious psychiatric illnesses such as schizophrenia, classically defined bipolar disorder, or severe aggression associated with autism,” and “given the risk for weight gain and long-term risk for cardiovascular and metabolic problems, the widespread and increasing use of atypical antipsychotic medications in children and adolescents should be reconsidered.”

About The Feinstein Institute for Medical Research

Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in cancer, leukemia, lymphoma, Parkinson’s disease, Alzheimer’s disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, inflammatory bowel disease, diabetes, human genetics, neuroimmunology, and medicinal chemistry. Feinstein researchers are developing new drugs and drug targets, and producing results where science meets the patient, annually enrolling some 10,000 subjects into clinical research programs.

About The Zucker Hillside Hospital

The Zucker Hillside Hospital is home to many of the nation’s experts on severe mental illness. In addition to treating patients in and out of the hospital, psychiatric research has been ongoing for decades and includes landmark studies on the treatment and course of first-episode psychotic patients. Genetics also plays a critical role in severe mental illness and scientists at the Zucker Hillside Hospital have identified several important risk genes. John Kane, MD, chair of psychiatry at Zucker Hillside, and his team of scientists recently received a $ 26 million federal grant to train psychiatric staff across the country to deliver state-of-the-art treatments for patients with a first episode of schizophrenia and to test whether it works to delay or alter the disabling course of the illness.

Contact: Jamie Talan

science writer-in-residence

516-562-1232 or 631-682-8781 (cell)

###







Read More

HAPPYneuron Launches Beta Program for Innovative Cognitive Rehab Tools at AMIA Conference in San Francisco

August 08, 2012     No comments


Capitola, CA (PRWEB) November 16, 2009

HAPPYneuron announces the launch of HAPPYneuron PRO, a suite of online cognitive rehab tools for a variety of cognitive disorders at the American Medical Informatics Association (AMIA) conference in San Francisco, California, on November 16-17, 2009.

A pioneering brain training and rehabilitation solutions firm, HAPPYneuron introduced its PRO platform, which delivers controlled rehabilitation treatments for impairments caused by neurotrauma, neuropsychiatric or neurodegenerative conditions including Traumatic Brain Injury, Depression, Schizophrenia, Mild Cognitive Impairment and Alzheimer’s disease, Stroke, ADD/ADHD and more.

HAPPYneuron PRO provides a series of cognitive stimulation exercises in the form of interactive flash games, each with multiple controllable variants, designed to target a particular set of cognitive functions and to heighten patient engagement. Cognitive skills rehabilitated include memory, attention, language, visual-spatial skills, executive function and all the related sub-brain functions.

Designed by leading neurologist Bernard Croisile, MD, PhD, reviewed by a wide range of clinical professionals, and validated by researchers, the HAPPYneuron PRO cognitive rehab tools leverage the power of the Web to deliver improved case management and objective measurements of the cognitive rehabilitation process. Patients benefit from an engaging rehab experience, supplemented with at-home participation.

“The HAPPYneuron PRO exercises are adapted from the successful game designs that have been validated by millions of HAPPYneuron users worldwide, thereby offering proven engagement for rehab patients,” says Laura Fay, CEO, HAPPYneuron, Inc.

Through the professional Web-based interface, the clinician or researcher can customize the treatment program, monitor patient compliance and performance, and supplement in-office rehab with in-home exercises, thus reducing cost and facilitating a more patient-centric rehabilitation program.

“The advantage of the HAPPYneuron PRO platform is that it allows individuals to receive a more consistent dose of cognitive enhancement, thereby enabling the flexibility to design innovative research studies not previously possible,” said Christopher R. Bowie, PhD, Dept Psychiatry & Psychology, Queen’s University, Ontario, Canada.

The HAPPYneuron PRO cognitive rehab tools are available in a range of membership levels suitable for individual therapist practices and large hospital systems alike. Free trials are available for all qualified professionals during the beta program phase. To learn more, visit http://www.happy-neuron-pro.com.

About HAPPYneuron, Inc.:

A pioneer in brain training and rehabilitation solutions, HAPPYneuron offers a broad range of scientifically validated, personalized programs in multi-media formats for children, adults and seniors. HAPPYneuron was co-founded by internationally acclaimed and award-winning neurologist, Bernard Croisile, MD PhD, and is dedicated to improving cognitive health through evidence based products for individuals and cognitive therapy professionals worldwide. HAPPYneuron is a majority owned subsidiary of Scientific Brain Training (NYSE Euronext: MLSBT).

This press release was distributed through PR Web by Senior Care Marketer (SeniorCareMarketer: http://www.SeniorCareMarketer.com) on behalf of the company listed above.

###







Related Schizophrenia Press Releases

Read More

Schizophrenia Gene?s Role May Be Broader, More Potent, than Thought

August 08, 2012     No comments

San Francisco, CA (Vocus) November 20, 2009

UCSF scientists studying nerve cells in fruit flies have uncovered a new function for a gene whose human equivalent may play a critical role in schizophrenia.

Scientists have known that the mutated form of the human gene ? one of three consistently associated with schizophrenia ? mildly disrupts the transmission of chemical signals between nerve cells in the brain.

The new study focuses on genes involved in ?adaptive plasticity,? the capacity of nerve cells to compensate for a wide range of perturbations and continue to function normally.

Studies ranging from fruit flies to human have shown that if a nerve cell is functionally impaired then the surrounding cells can compensate and restore normal cell-to-cell communication. This type of ?adaptive plasticity? stabilizes brain function, but the molecules involved remain largely unknown.

In the current study, the team screened 276 mutated, or disabled, fly genes to determine if their absence revealed a role in adaptive plasticity in the fruit fly nervous system. While absence of most of the genes had no impact on adaptive plasticity, the absence of the gene known as dysbindin did.

The finding, reported in the November 20, 2009 issue of Science, was dramatic, says the senior author of the study, Graeme Davis, PhD, Albert Bowers Endowed Professor and Chair of the Department of Biochemistry and Biophysics at UCSF.

?Mutation of the gene completely prevented the capacity of the neural circuitry to respond to an experimental perturbation, to be adaptive. The dysbindin mutation was one of very few gene mutations that had this effect,? he says. ?The gene?s unique function suggests to us that impaired adaptive plasticity may have particular relevance to the cause or progression of schizophrenia.?

Schizophrenia generally emerges in people in their late teens or early adulthood. It?s possible, says Davis, that normal developmental changes at this stage of life represent a significant stress to ongoing, stable neural function. If so, he says, the capacity of the nervous system to respond to these normal developmental changes ? which in a sense are perturbations ? may be impaired in people who become schizophrenic.

The next question the researchers will ask,? he says, ?is whether absence of the dysbindin gene causes a blockade of adaptive plasticity in mice and whether other genes linked to schizophrenia cause a similar block of adaptive plasticity.?

The study, led by Dion K. Dickman, PhD, a postdoctoral fellow in the Davis lab, also revealed a more general insight into the mechanisms of adaptive plasticity because they were able to rule out the involvement of numerous genes that were previously considered as candidate players.

?We tested numerous mutations that alter neural function, and most showed perfectly fine adaptive plasticity.? he says, ?This suggests that there are distinct roles for genes at the synapse, some support normal neural function while a small subset control adaptive plasticity.?

The phenomenon of adaptive plasticity, a burgeoning area of inquiry in the neurosciences, was first recognized more than a decade ago. Early studies by Davis, a pioneer of the field, showed that when genes functioning in the fruit fly nervous system were mutated, the nervous system would compensate and the animals appeared remarkably normal.

Davis has explored this and related phenomena at the neuromuscular junction in the fruit fly, or Drosophila melanogaster. He?s been asking how neural function is stabilized but also how the physical connections between nerve cells are stabilized and maintained throughout life. He would like to understand how this process sometimes fails, leading to neurodegeneration, such as occurs in amyotrophic lateral sclerosis, or ALS.

?It?s become clear that the nervous system is remarkably stable, but not as one might suspect,? says Davis. ?It is continuously responsive to a changing environment, which allows us to learn and remember and to respond to environmental change. There probably are many processes that are sensing the environment, continually updating neural function and neural structure in order to keep the brain stable. If we can understand how stability is maintained in the nervous system, perhaps we could understand what happens when stability is lost and disease ensues.?

?These are big questions that reach far beyond our current understanding of brain function,? he says. ?This is the power and importance of basic science. By studying fundamental questions, you can discover unexpected phenomenon and also create new perspectives for understanding existing diseases, even if the human genes are known.? The new finding, he says, ?may add a new dimension to the conversation about the origins of schizophrenia.?

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

Related links:

Davis lab: http://biochemistry.ucsf.edu/labs/davis/

Source: Jennifer O?Brien (415) 476-2557

Web: http://www.ucsf.edu

###







Read More

CME Outfitters Announces New neuroscienceCME Live and On Demand Broadcast: ‘Addressing Barriers to Care: Strategies for the Management of Patients with Schizophrenia’

August 06, 2012     No comments

Rockville, MD (PRWEB) November 23, 2009

CME Outfitters, LLC, (CMEO) an award-winning accredited provider of multidisciplinary continuing education (CE), in co-sponsorship with Indiana University School of Medicine and CME LLC, is pleased to announce an upcoming interactive, evidence-based neuroscienceCME Live and On Demand continuing education activity titled “Addressing Barriers to Care: Strategies for the Management of Patients with Schizophrenia.”

Offered as a simultaneous satellite broadcast, webcast, and telephone audioconference premiering Wednesday, December 16, 2009, from 12:00 p.m.-1:00 p.m. ET, the activity will offer clinicians optimal strategies to more effectively manage individuals with schizophrenia across the continuum of care. This activity also includes a special “After the Show” segment from 1:00 p.m.-1:30 p.m. ET during which the faculty answers additional audience questions in an informal Q&A session. The recorded webcast will re-air from 3:00 p.m.-4:00 p.m. ET. This CE activity will also be available on demand as a webcast, podcast, and telephone audioconference shortly after the broadcast premiere.

There is no fee to participate or receive CE credit for this activity; however, registration is required. Three forms of registration are accepted:

Online: Visit the activity details page at http://www.neuroscienceCME.com/PR400 and click the Register for Live Webcast icon.

Phone: Call 877.CME.PROS (877.263.7767).

Fax: Visit the activity details page at http://www.neuroscienceCME.com/PR400, print and complete the activity details form, and fax to 240.243.1033.

Statement of Need:

Until the past decade, there was generally a pessimistic attitude about the treatment of patients with schizophrenia and their outcomes. One key concept that has been identified as critical in optimizing the care and outcomes of patients is continuity of care by a team of healthcare providers. Continuity of care is widely viewed as a key quality indicator for outpatient mental health care and is essential to prevention of relapse and re-hospitalization.

Yet, progress has lagged in the implementation and measurement of continuity of care in clinical practice. In a recent educational activity by CME Outfitters, over 220 psychiatrists responded that their main reason for not changing practice immediately regarding continuity of care was they did not know where to start, demonstrating a gap in knowledge and performance regarding the implementation of this process in clinical practice. A first step to improving care is identifying the barriers that exist. Patient barriers, physician barriers and system barriers can be significant obstacles requiring education of the entire mental healthcare team in order to begin to break down the walls and allow clinicians to provide the best care for each patient.

The identification of the barriers can be the first step in empowering both the provider and the patient. This can highlight to psychiatrists, other healthcare providers, payors, and healthcare systems what barriers may exist and how they are impacting the outcomes and lives of patients.

In this neuroscienceCME Live and On Demand activity, faculty will highlight barriers to optimal care and their impact on the outcomes and lives of patients with schizophrenia and propose practical strategies and tools that can be utilized to improve the care of patients with schizophrenia.

Moderator:

John W. Newcomer, MD

Gregory B. Couch Professor of Psychiatry, Psychology and Medicine

Director, Clinical Trials Unit, Institute of Clinical and Translational Sciences (ICTS)

Director, Regulatory Support Center, ICTS

Medical Director, Center for Clinical Studies

Washington University School of Medicine

St. Louis, MO

Faculty:

Henry A. Nasrallah, MD

Professor of Psychiatry and Neuroscience

University of Cincinnati College of Medicine

Cincinnati, OH

Dawn I. Velligan, PhD

Professor and Co-Director

Division of Schizophrenia and Related Disorders

Department of Psychiatry

The University of Texas Health Science Center at San Antonio

San Antonio, TX

Learning Objectives:

At the end of this CE activity, participants should be able to:

Assess key barriers in practice that impact continuity of care in the management of patients with schizophrenia.
Implement treatment plans in concordance with patients that focus on improving continuity of care.
Incorporate tools and measures in practice to improve discharge transitions of patients with schizophrenia.

Target Audience:

Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals interested in the management of patients with schizophrenia.

Financial Support:

This CME/CE-certified activity is supported by an educational grant from Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC.

Credit Information:

This activity offers CE credit for:

Physicians (ACCME/AMA PRA Category 1)
Nurses (CNE)
Pharmacists (ACPE)
Psychologists (APA)
Social Workers (NASW)
Certified Case Managers (CCMC)
All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.

Credit Expiration Date: Thursday, December 16, 2010

Post-tests, credit request forms, and activity evaluations can be completed online at neuroscienceCME.com (click on the Testing/Certification link under the Activities tab–requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). Otherwise, participants should fully complete and return both the credit request form and activity evaluation located within the course guide for this activity. A certificate or statement of credit will be mailed within 4-6 weeks to all who successfully complete these requirements.

About CME Outfitters:

CME Outfitters develops and distributes live, recorded, print, and web-based educational activities to thousands of clinicians each year and offers expert accreditation services for non-accredited organizations. For a complete catalog of certified activities, please visit http://www.cmeoutfitters.com, http://www.neuroscienceCME.com, or call 877.CME.PROS (877.263.7767).

About neuroscienceCME:

neuroscienceCME.com is the award-winning web portal serving clinicians, educators, and researchers in the neurosciences. Launched in October 2006, neuroscienceCME.com was custom designed to fill an identified gap in online resources for professionals around the world who are practicing in areas related to psychiatry, sleep disorders, addiction and substance abuse, ADHD, and other areas related to brain function. The site’s primary mission is to be the professional’s central forum for accessing, debating, synthesizing, and implementing the latest findings and best practices in the neurosciences. Clinical Compass?, a bi-weekly e-newsletter published by CME Outfitters, is a convenient way to stay informed of all neuroscienceCME news and information. To subscribe, visit http://www.neuroscienceCME.com and click on “Subscribe to Clinical Compass?.”

About neuroscienceCME Live and On Demand:

neuroscienceCME Live and On Demand is a one-hour, live, interactive CE activity offering cutting-edge insights from national experts and clinicians to physicians and healthcare providers in their home, office, or healthcare setting. Utilizing multiple levels of technology (webcast, satellite, and telephone), the panel discussion encourages interaction, reviews real-world scenarios, and shares best practices to improve patient care. An extended 30-minute “After the Show” segment has the faculty remain on the set to answer additional participant questions, address challenging cases, and focus on providing tools for clinicians to improve their practice. Live web-based instant polling allows participants an additional opportunity to provide real-time feedback regarding issues clinicians face in practice. CE certificates are available to participants at neuroscienceCME.com upon completion of each activity. Special Archive Drive dates following the premiere date target registrants who were unable to attend. On demand webcasts and podcasts are available at neuroscienceCME.com for one year after the premiere date. Podcasts are also available in the Science & Medicine directory of iTunes.

Contact: Jessica Primanzon

CME Outfitters, LLC

240.243.1308 direct

240.243.1033 fax

###







Read More

Jill Bolte Taylor Ph.D to Join Host Doreen Agostino on ‘Align Shine Prosper’ Show on the VoiceAmerica Talk Radio Network

August 06, 2012     No comments

Phoenix, AZ (PRWEB) December 11, 2009

Modavox, Inc. (OTCBB:MDVX -News) Internet broadcasting pioneer, producing & syndicating online audio & video, today announced international best-selling author, researcher & lecturer, Dr. Jill Bolte Taylor, will join Doreen Agostino, host of ‘Align Shine Prosper’ on VoiceAmerica 7th Wave Channel http://www.7thwavenetwork.com Wednesday, December 16, 2009 at 3 pm Pacific.

As a trained & published neuroanatomist (a scientist who specializes in how the brain works) Dr. Jill’s specialty was the post mortem investigation of the human brain as it relates to schizophrenia & the severe mental illnesses. Because her brother had been diagnosed with the brain disorder schizophrenia, Dr. Jill served on the Board of Directors of the National NAMI organization (National Alliance on Mental Illness) between 1994 & 1997. Dr. Jill currently serves as President of the Greater Bloomington Affiliate of NAMI in Bloomington, Indiana.

As irony would have it, on December 10, 1996, Dr. Jill woke up to discover she was experiencing a rare form of stroke, an arterio- venous malformation (AVM). The experience was life-changing. Within hours, Dr. Jill could no longer walk, talk, read or write. As she tried to phone for help, she was aware that the left hemisphere of her brain was shutting down, taking with it her language, organization & other analytical skills. Without the dominant left side of her brain controlling her thoughts, Dr. Jill says, her left mind went silent, leaving only the right side of the brain functioning.

Through the right hemisphere, Dr. Jill says her consciousness shifted away from reality & the trauma her body was enduring, into a place of inner peace & Nirvana. Two & a half weeks later, on December 27, 1996, she underwent major brain surgery at Massachusetts General Hospital (MGH) to remove a golf ball sized blood clot that was placing pressure on the language centers in the left hemisphere of her brain.

Not only did it take Dr. Jill 8 years to successfully rebuild her brain from the inside out after her stroke & major surgery, but she also discovered a better quality of life, through finding balance between both hemispheres of her brain. She’s now an artist as well as a scientist, creating anatomically correct stained-glass brains that are sold as fine art.

In her New York Times bestselling book, My Stroke of Insight: A Brain Scientist’s Personal Journey, Dr. Jill explains in scientific detail exactly what happened during her stroke & how she recovered. It also takes a closer look at how both the left & right hemispheres of the brain work & how people can be more conscious with when & how they capitalize on the skills of each hemisphere.

In May 2008, TIME Magazine named Dr. Jill as one of the 100 Most Influential People in the World & she was the premiere guest on Oprah’s Soul Series webcast. In addition, her interview with Oprah & Dr. Mehmet Oz on the Oprah Winfrey Show aired on October 21, 2008.

Dr. Jill was a speaker at the TED Conference (Technology, Entertainment, Design). Its mission is to provide TED talks devoted to ‘ideas worth spreading.’

Dr. Jill keynotes throughout the country & is committed to educating the public about the beauty & resiliency of the human brain, neurological rehabilitation & the value of brain donation for research. As a public speaker, Dr. Jill’s presentations are specifically designed for the education of both the lay public & health professionals. Intended to be “Brain 101″ presentations, her audiences are made up of people who seek to better understand the

beautiful human brain.

Dr. Jill’s presentation style is stippled with both appropriate humour & beautiful slides of the brain. She is a dynamic speaker who makes the subject of the human brain not only manageable but interesting, exciting & intellectually stimulating.

In addition, Dr. Jill is the consulting neuroanatomist, for the Midwest Proton Radiotherapy Institute (MPRI) housed at the Indiana University Cyclotron.

‘Align Shine Prosper’ airs Wednesdays 3 PM Pacific /5 PM Central /6 PM Eastern on VoiceAmerica’s 7th Wave Network. To access the show go to http://www.modavox.com/voiceamerica/vshow.aspx?sid=1582

All shows are available in Doreen’s Content Library on 7th Wave Network for on-demand pod cast & download.

The VoiceAmericaTM Network offers the latest conversations in a talk radio format, providing education, interaction & advice on key issues live, on-demand as well as through pod cast download. If you are interested in hosting a talk radio show on VoiceAmerica Network, contact Jeff Spenard, President of Internet Radio at 480-294-6417.

For advertising / sponsorship information or other show details contact Executive Producer Mark Pace at 480-553-5745.

ABOUT Doreen Agostino:

In the mid 80s, a quest for truth led Doreen to contemporary science & radical new interpretations of life in a material world. Mind & heart open, Doreen trail blazed unchartered territory to explore inner world technology; the subjective nature of mind. Two & a half decades of exploring, research, study & experiential learning, revealed another reality & a fresh perspective.

Retired early from 33 years in a Fortune 500 Company, in 2007 Doreen chose the power of love over chemo & radiation, to transform cancer cells into happy cells & restore her biology naturally & permanently.

Doreen is a member of The Institute of Noetic Sciences, The Institute of Heart Math, and the Global Coherence Project. Certtified in 2nd Degree Reiki, Holodynamics; author & Silva Method Graduate, Doreen inspires entrepreneurs & truth seekers to expand their field of perception, for a greater sense of life experience through inner truth or higher awareness.

Seeding a new conscious world, Doreen hosts world changing, leading edge scientists, physicists, doctors & luminaries every Wednesday on Align Shine Prosper iRadio, to expand new awareness & advance global coherence.

About VoiceAmerica / Modavox:

Since 1999, the VoiceAmerica Talk Radio Network has been streaming live Internet talk radio programs, featuring more than 300 hosts broadcasting on seven genre-based channels: its flagship VoiceAmerica? Variety Channel, VoiceAmerica? Health & Wellness Channel, VoiceAmerica? Business Channel, VoiceAmerica Sports, 7th Wave Network, The Green Talk Network and Power Up Motorsports Channel. VoiceAmerica? is the single largest producer of original Internet talk radio programming in the world. http://voiceamerica.com.

(OTC.BB MDVX), Modavox is the leading producer and distributor of online talk radio content, streaming approximately 250 hours of live programs and scheduled replays weekly on its Modavox VoiceAmerica? Network (http://www.voiceamerica.com). Modavox, Inc. (http://www.modavox.com) is a pioneer in internet broadcasting, producing and syndicating online audio and video, and offering innovative, effective and comprehensive online tools for reaching targeted niche communities worldwide. Through its patented Modavox technology, Modavox delivers content straight to desktops and Internet-enabled devices. Modavox provides managed access for live and on-demand internet broadcasting and syndication, content management, online meetings, event management, enterprise communications and distance learning.

Modavox provides complete production, delivery, and on-demand archive delivery for VoiceAmerica hosts. At the center of this offering is Modavox’s patented BoomBox? technology that provides show hosts with instant broadcasting capabilities from their own websites and with instant syndication through affiliate sites. In addition, Modavox assists in the creation of sponsorship, advertising and advanced distribution models for VoiceAmerica programming.

Forward-Looking Statements:

This release contains “forward-looking statements” for purposes of the Securities and Exchange Commission’s “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. These forward-looking statements are subject to various risks and uncertainties that could cause Modavox’s actual results to differ materially from those currently anticipated, including the risk factors identified in Modavox’s filings with the Securities and Exchange Commission.

###







Read More
« Older posts
Powered by WordPress | Designed by: best suv | Thanks to toyota suv, infiniti suv and lexus suv